All Stories

Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs.

Apr 23, 2025 - 15:51
 0
Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model
Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs.
Read More

Tags:

Previous Article

Elon Musk To Cut DOGE Work To Nearly Half His Waking Hours

Next Article

Agua Bendita launches immersive summer pop-ups at Bloomingdale's across the U.S.

Related Posts

Clario continues acquisition spree with imaging specialist NeuroRx

Clario continues acquisition spree with imaging special...

Mar 18, 2025  0

CF-focused Sionna goes public in $135M IPO, while Aardvark plots $103M listing

CF-focused Sionna goes public in $135M IPO, while Aardv...

Feb 9, 2025  0

Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash

Sutro discards CEO, 50% of staff, sole clinical-stage A...

Mar 14, 2025  0